Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remiss...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2023-04, Vol.16 (1), p.43-43, Article 43
Main Authors: Pavlovsky, Carolina, Vasconcelos Cordoba, Bianca, Sanchez, María Belén, Moiraghi, Beatriz, Varela, Ana, Custidiano, Rosario, Fernandez, Isolda, Freitas, Maria Josefina, Ventriglia, Maria Verónica, Bendek, Georgina, Mariano, Romina, Mela Osorio, María José, Pavlovsky, Miguel Angel, de Labanca, Ana García, Foncuberta, Cecilia, Giere, Isabel, Vera, Masiel, Juni, Mariana, Mordoh, Jose, Sanchez Avalos, Julio Cesar, Cueto, Gerardo, Miranda, Silvia, Levy, Estrella Mariel, Bianchini, Michele
Format: Article
Language:English
Subjects:
Accuracy
Biomarkers
Chronic myeloid leukemia
Cloning
Correspondence
Cytokines
Data mining
Hematology
Humans
Interleukin 6
Kinases
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Machine learning
Monocyte chemoattractant protein 1
Myeloid leukemia
Oncology
Plasma
Plasma levels
Predictive factors
Protein Kinase Inhibitors
Remission
Remission (Medicine)
Remission Induction
Stem cells
Treatment free remission
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1 /IL-6 patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-023-01440-6